Affordable Access

Publisher Website

Validating an empiric sulfadiazine-trimethoprim dosage regimen for treatment of Escherichia coli and Staphylococcus delphini infections in mink (Neovison vison).

  • Ronaghinia, Amir Atabak1, 2
  • Nikolaisen, Nanett Kvist2, 3
  • Hansen, Stine Green2
  • Poulsen, Helle Harding4
  • Frandsen, Henrik Lauritz5
  • Struve, Tina2
  • Toutain, Pierre-Louis6, 7
  • Damborg, Peter1
  • 1 Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark. , (Denmark)
  • 2 Kopenhagen Diagnostics, Department of Health and Diagnostics, Kopenhagen Fur a.m.b.a, Glostrup, Denmark. , (Denmark)
  • 3 National Food Institute, Research Group for Microbiology and Hygiene, Technical University of Denmark, Kongens Lyngby, Denmark. , (Denmark)
  • 4 Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark. , (Denmark)
  • 5 National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark. , (Denmark)
  • 6 Royal Veterinary College, University of London, London, UK.
  • 7 INTHERES, Université de Toulouse, INRA, ENVT, Toulouse, France. , (France)
Published Article
Journal of veterinary pharmacology and therapeutics
Publication Date
Sep 13, 2020
DOI: 10.1111/jvp.12894
PMID: 32924166


Antimicrobial agents are used extensively off-label in mink, as almost no agents are registered for this animal species. Pharmacokinetic (PK) and pharmacodynamic (PD) data are required to determine antimicrobial dosages specifically targeting mink bacterial pathogens. The aims of this study were to assess, in a PKPD framework, the empirical dosage regimen for a combination of trimethoprim (TMP) and sulfadiazine (SDZ) in mink, and secondarily to produce data for future setting of clinical breakpoints. TMP and SDZ PK parameters were obtained experimentally in 22 minks following IV or oral administration of TMP/SDZ (30 mg/kg, i.e. 5 mg/kg TMP and 25 mg/kg SDZ). fAUC/MIC with a target value of 24 hr was selected as the PKPD index predictive of TMP/SDZ efficacy. Using a modeling approach, PKPD cutoffs for TMP and SDZ were determined as 0.062 and 16 mg/L, respectively. By incorporating an anticipated potentiation effect of SDZ on TMP against Escherichia coli and Staphylococcus delphini, the PKPD cutoff of TMP was revised to 0.312 mg/L, which is above the tentative epidemiological cutoffs (TECOFF) for these species. The current empirical TMP/SDZ dosage regimen (30 mg/kg, PO, once daily) therefore appears adequate for treatment of wild-type E. coli and S. delphini infections in mink. © 2020 John Wiley & Sons Ltd.

Report this publication


Seen <100 times